Cardiol Therapeutics Inc.
CRDL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001702123
No open-market purchases or sales by Cardiol Therapeutics Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $31.3M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Cardiol Therapeutics Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 33 | 35 | +2 |
| Shares | 6.69M | 6.37M | −315.2K (−4.7%) |
| Value | $5.97M | $5.78M | −$190.2K (−3.2%) |
New holders (8)
Institutions that held Cardiol Therapeutics Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Credit Suisse AG | 50,000 | $62.0K | 0.00% |
| FNY Investment Advisers, LLC | 33,305 | $30.0K | 0.02% |
| MONECO Advisors, LLC | 14,000 | $12.5K | 0.00% |
| HRT Financial LP | 12,345 | $11.0K | 0.00% |
| Bank of America Corp | 4,000 | $3.58K | 0.00% |
| Wells Fargo & Company | 150 | $137 | 0.00% |
| Morgan Stanley | 100 | $90 | 0.00% |
| Toronto Dominion Bank | 26 | $23 | 0.00% |
Sold out (6)
Institutions that held Cardiol Therapeutics Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 36,613 | $32.6K |
| Natixis | 25,000 | $22.4K |
| Citadel Advisors LLC | 17,743 | $15.8K |
| Two Sigma Securities, LLC | 13,359 | $11.9K |
| NewSquare Capital LLC | 700 | $623 |
| Oliver Lagore Vanvalin Investment Group | 500 | $445 |